Table 2.
Characteristics of 71 discharged patients recovered from COVID-19.
| No. (%) |
|||||||||
|---|---|---|---|---|---|---|---|---|---|
| Total (N = 71) | Group A (n = 44) | Group B (n = 27) | Positive recovery a |
Persistent negative b | P1 value c | P2 value d | |||
| Total (N = 19) | Group A (n = 16) | Group B (n = 3) | (n = 52) | ||||||
| Age, Median (IQR), y | 47 (39.5-56.5) | 47 (39.0-56.0) | 48 (42.5-61.5) | 48 (42.0-64.5) | 54 (46.3-66.3) | 20 (18-44) | 46 (39.0-53.0) | 0.29 | 0.7 |
| Gender | |||||||||
| Female | 29 (40.8) | 14 (31.8) | 12 (44.4) | 7 (9.9) | 6 (8.5) | 1 (1.4) | 22 (31.0) | 0.79 | 0.32 |
| Male | 42 (59.2) | 30 (68.2) | 15 (55.6) | 12 (16.9) | 10 (14.1) | 2 (2.8) | 30 (4.2) | ||
| Length of hospital stay (IQR), d | 16 (12.0-22.0) | 14.5 (10.0-17.0) | 25 (14.5-27.0) | 17 (12.0-19.5) | 15.5 (12.5-19.0) | 25 (10-29) | 16 (12.0-24.0) | 0.64 | <0.0001 |
| Course of disease (IQR), d | 20 (16.0-27.0) | 18 (15.0-23.0) | 27 (19.0-30.5) | 20 (16.0-24.5) | 17.5 (15.5-23.0) | 30 (20-32) | 21 (16.0-28.0) | 0.44 | 0.0005 |
| Severity | |||||||||
| Severe | 10 (14.1) | 6 (13.6) | 4 (14.8) | 4 (5.6) | 3 (4.2) | 1 (1.4) | 6 (8.5) | 0.44 | 1 |
| Mild | 61 (85.9) | 38 (86.4) | 23 (85.2) | 15 (21.2) | 13 (18.3) | 2 (2.8) | 46 (64.7) | ||
| Glucocorticoid therapy | 18 (25.4) | 11 (25.0) | 7 (25.9) | 4 (5.6) | 3 (4.2) | 1 (1.4) | 14 (19.7) | 0.76 | 1 |
Abbreviations: IQR, interquartile range; COVID-19, coronavirus disease 2019; a indicate patients with SARS-VoC-2 RNA turned to positive, and b indicate patients with SARS-VoC-2 RNA remained negative; c P1 values indicate differences between the patients with positive SARS-VoC-2 RNA and patients with consistently negative SARS-VoC-2 RNA; d P2 values indicate differences between the Group A and Group B. P < 0.05 was considered statistically significant.